m6A Target Gene Information
General Information of the m6A Target Gene (ID: M6ATAR00555)
Full List of m6A Methylation Regulator of This Target Gene and Corresponding Disease/Drug Response(s)
PDK4
can be regulated by the following regulator(s), and cause disease/drug response(s). You can browse detail information of regulator(s) or disease/drug response(s).
Browse Regulator
Browse Disease
Methyltransferase-like 3 (METTL3) [WRITER]
Representative RNA-seq result indicating the expression of this target gene regulated by METTL3 | ||
Cell Line | LX2 cell line | Homo sapiens |
Treatment: shMETTL3 LX2 cells
Control: shLuc LX2 cells
|
GSE207909 | |
Regulation |
|
logFC: -1.03E+01 p-value: 3.59E-12 |
More Results | Click to View More RNA-seq Results | |
Representative RIP-seq result supporting the interaction between PDK4 and the regulator | ||
Cell Line | MDA-MB-231 | Homo sapiens |
Regulation | logFC: 5.02E+00 | GSE60213 |
In total 1 item(s) under this regulator | ||||
Experiment 1 Reporting the m6A Methylation Regulator of This Target Gene | [1] | |||
Response Summary | m6A regulates glycolysis of cancer cells through Pyruvate dehydrogenase kinase isoform 4 (PDK4). Knockdown of Mettl3 significantly attenuated m6A antibody enriched PDK4 mRNA in Huh7 cells. It reveals that m6A regulates glycolysis of cancer cells through PDK4. | |||
Target Regulation | Up regulation | |||
Responsed Disease | Solid tumour/cancer | ICD-11: 2A00-2F9Z | ||
Pathway Response | Glycerolipid metabolism | hsa00561 | ||
Cell Process | Glycolysis | |||
In-vitro Model | SiHa | Cervical squamous cell carcinoma | Homo sapiens | CVCL_0032 |
MDA-MB-231 | Breast adenocarcinoma | Homo sapiens | CVCL_0062 | |
Huh-7 | Adult hepatocellular carcinoma | Homo sapiens | CVCL_0336 | |
Hep-G2 | Hepatoblastoma | Homo sapiens | CVCL_0027 | |
HeLa | Endocervical adenocarcinoma | Homo sapiens | CVCL_0030 | |
In-vivo Model | As to the subcutaneous transplanted model, WT Vec, Mettl3 Mut/-+vec, WTPDK4, Mettl3 Mut/-+vecPDK4 cells (2 × 10 6 per mouse, n = 10 for each group) were diluted in 200 uL normal medium + 200 uL Matrigel (BD Biosciences) and subcutaneously injected into immunodeficient mice to investigate tumor growth. | |||
Solid tumour/cancer [ICD-11: 2A00-2F9Z]
In total 1 item(s) under this disease | ||||
Experiment 1 Reporting the m6A-centered Disease Response | [1] | |||
Response Summary | m6A regulates glycolysis of cancer cells through Pyruvate dehydrogenase kinase isoform 4 (PDK4). Knockdown of Mettl3 significantly attenuated m6A antibody enriched PDK4 mRNA in Huh7 cells. It reveals that m6A regulates glycolysis of cancer cells through PDK4. | |||
Responsed Disease | Solid tumour/cancer [ICD-11: 2A00-2F9Z] | |||
Target Regulator | Methyltransferase-like 3 (METTL3) | WRITER | ||
Target Regulation | Up regulation | |||
Pathway Response | Glycerolipid metabolism | hsa00561 | ||
Cell Process | Glycolysis | |||
In-vitro Model | SiHa | Cervical squamous cell carcinoma | Homo sapiens | CVCL_0032 |
MDA-MB-231 | Breast adenocarcinoma | Homo sapiens | CVCL_0062 | |
Huh-7 | Adult hepatocellular carcinoma | Homo sapiens | CVCL_0336 | |
Hep-G2 | Hepatoblastoma | Homo sapiens | CVCL_0027 | |
HeLa | Endocervical adenocarcinoma | Homo sapiens | CVCL_0030 | |
In-vivo Model | As to the subcutaneous transplanted model, WT Vec, Mettl3 Mut/-+vec, WTPDK4, Mettl3 Mut/-+vecPDK4 cells (2 × 10 6 per mouse, n = 10 for each group) were diluted in 200 uL normal medium + 200 uL Matrigel (BD Biosciences) and subcutaneously injected into immunodeficient mice to investigate tumor growth. | |||